Welcome back to Audioboards!
I’m so glad you’re tuning in today. Whether you’re on shift in the ER, running a busy primary care clinic, or rounding on the wards, skin and soft tissue infections—SSTIs—are an absolute staple of everyday clinical practice. But let’s be honest: they’re also one of the most common reasons for over-prescribing broad-spectrum antibiotics. How many times have you seen every red leg on the floor placed on empiric Vancomycin and Zosyn?
Today, we’re cutting through the noise and breaking down the Infectious Diseases Society of America (IDSA) guidelines into a clear, actionable framework you can use at the bedside.
Whenever you evaluate a skin infection, I want you to pause and ask yourself one foundational question before you even open up your order set: Is this infection purulent or non-purulent? Once you split the path there, you simply grade the severity—mild, moderate, or severe—and your treatment strategy becomes crystal clear. Let's walk through it together.
Path 1: Purulent Infections (Abscesses, Furuncles, & Carbuncles)
Let's start with purulent infections. We’re talking about cutaneous abscesses, furuncles, and carbuncles. Pathogen-wise, Staphylococcus aureus is king here—specifically Methicillin-Resistant S. aureus (MRSA) and Methicillin-Susceptible S. aureus (MSSA).
When you’re dealing with pus, the IDSA breaks management into three severity tiers:
Mild Purulent: This is your systemically well patient with a localized, fluctuant abscess.
The Strategy: Incision and drainage (I&D) alone. That’s right—no oral or IV antibiotics are necessary for typical mild cases! Source control is the cure.
Moderate Purulent: This is an abscess accompanied by Systemic Inflammatory Response Syndrome (SIRS criteria)—think a fever above 38°C (100.4°F) or under 36°C, heart rate over 90, respiratory rate over 24, or abnormal white count.
The Strategy: Perform your I&D, plus start a 5 to 7 day course of oral empiric MRSA coverage. Your primary outpatient go-to options here are Trimethoprim-sulfamethoxazole (TMP-SMX) or Doxycycline.
Severe Purulent: Patients who have failed oral therapy, show signs of systemic toxicity, have hemodynamic instability, or are severely immunocompromised.
The Strategy: Prompt I&D combined with parenteral (IV) MRSA coverage. First-line IV therapy remains Vancomycin (15–20 mg/kg Q8–12h) or Daptomycin.
Key Takeaway: For purulent infections, incision and drainage is your primary therapeutic maneuver. Antibiotics are merely an adjunct when systemic signs or host vulnerabilities are present.
Path 2: Non-Purulent Infections (Cellulitis & Erysipelas)
Now, let's flip the script to non-purulent SSTIs—classic cellulitis and erysipelas. You see spreading erythema, warmth, and induration, but there is no pus, breakdown, or fluctuance.
Here’s a common clinical misconception: MRSA is actually uncommon in typical, non-purulent cellulitis! These infections are overwhelmingly driven by Beta-hemolytic streptococci (especially Group A Strep), with MSSA playing a secondary role.
Here is how the IDSA guides our treatment based on severity:
Mild Non-Purulent: Typical, localized cellulitis in a systemically well patient.
The Strategy: Targeted oral streptococcal coverage. Cephalexin (500 mg four times daily) is your workhorse. If your patient has a penicillin allergy, Clindamycin or Azithromycin can be considered based on local resistance patterns.
Moderate Non-Purulent: Cellulitis accompanied by systemic signs of infection (SIRS criteria).
The Strategy: IV mono-therapy targeting Streptococci and MSSA. Options include Cefazolin (1–2 g IV Q8h), Ceftriaxone, or IV Penicillin G.
Severe Non-Purulent: Rapidly spreading infection, bullae, skin sloughing, severe pain out of proportion to exam, or hemodynamic instability.
The Strategy: Emergent surgical evaluation to rule out necrotizing fasciitis, along with broad-spectrum IV empirical coverage: Vancomycin plus Piperacillin-tazobactam (Zosyn).
A huge practice-changing tip on duration:
How long do we treat uncomplicated cellulitis? 5 days.
The IDSA guidelines emphasize that a 5-day course of directed oral therapy is just as effective as 10 days, provided the patient shows clinical improvement by day 5. Remember to remind your patients (and team!) that mild lingering erythema is normal due to ongoing tissue inflammation—it doesn't mean the active infection is failing therapy.
Red Flags: Necrotizing Soft Tissue Infections (NSTIs)
Now, I want to talk about the scenario that keeps every clinician up at night: Necrotizing Fasciitis.
When you are examining a soft tissue infection, always keep your eyes open for these high-yield red flags:
Pain out of proportion to physical exam findings.
Rapid progression of redness or edema despite ongoing antibiotic therapy.
Crepitus (gas in the soft tissue), bullae, or purple/ecchymotic skin changes.
Systemic toxicity, altered mental status, or refractory hypotension.
If you suspect a necrotizing infection, please do not delay for imaging or lab risk scores like the LRINEC score. Your immediate next step is a STAT surgical consult for surgical exploration and debridement. On the medical side, you’ll start broad IV coverage with Vancomycin, Zosyn, and Clindamycin—which is added specifically for its antitoxin effect against toxin-producing Strep and Staph species.
Special Scenarios & Recurrent Cellulitis
To round out the guidelines, let's touch on a few unique scenarios you’ll run into on shift:
Animal and Human Bites: Always cover Pasteurella multocida (cats/dogs) or Eikenella corrodens (humans) alongside oral anaerobes. Your drug of choice is Amoxicillin-clavulanate (Augmentin) orally, or Ampicillin-sulbactam (Unasyn) intravenously.
Surgical Site Infections: Suture removal plus drainage is mandatory. Systemic antibiotics are only needed if there's significant surrounding erythema (>5 cm) or systemic signs.
Recurrent Cellulitis: If a patient has 3 to 4 episodes per year despite treating the acute infection, first address predisposing factors—treat tinea pedis (toe web intertrigo), optimize venous stasis edema, and manage lymphedema. If recurrences continue, IDSA supports low-dose prophylactic antibiotics, such as oral Penicillin V or Erythromycin twice daily.
Before I let you go, let's distill this entire guideline into three simple rules to take to your next shift:
Classify first: Purulent = think Staph/MRSA and prioritize I&D. Non-purulent = think Strep and prioritize targeted beta-lactams.
Keep courses short: 5 days of targeted oral antibiotics for uncomplicated cellulitis if the patient is improving.
Act fast on red flags: Severe pain out of proportion or systemic toxicity requires immediate surgical evaluation.
Thanks for listening to AudioBoards. Stay tuned for more educational content in our next episode! The views and opinions expressed on the AudioBoards Podcast do not necessarily reflect those of our employers. This podcast is for educational purposes only and should not be used to diagnose or treat any medical conditions. It is not a substitute for professional medical advice. Always consult a qualified, board-certified healthcare provider for any medical concern.
.png)
